Q3 report confirms steady progress for Iconovo

Biostock published November 4th an article about Iconovo that can be found in its entirety below During Q2 and Q3, Iconovo took several steps to put…

Increased market potential for Iconovo’s inhalation platforms

Biostock published October 9th an article about Iconovo that can be found in its entirety below Swedish inhalation company Iconovo offer a faster way…

Iconovo intensifies global business development

The Q2 report released by Iconovo last week underlines an impressive first half of 2020 for the inhalation device company. Besides reaching several important…

Deal gives Iconovo long-term revenue potential

. In July, Iconovo announced it had signed a regional licensing agreement with BNC Korea for the development of two inhalation capsule formulations…

Iconovo adds business development experience with new CEO

So far, 2020 has brought several advancements for the Swedish dry powder inhaler company Iconovo. A major stepping stone was the change of CEO in April.…

Iconovo strengthens international intellectual property

2020 has been a year of intellectual property expansion for dry powder inhaler developer Iconovo Much of that expansion has come within Sweden and the…

Iconovo in collaboration with Malmö​​​​​​​ University

Iconovo’s expertise in developing inhalers and inhalation platforms for treating respiratory diseases has been key to generating several important collaborations.…

Iconovo’s ICOcap inhaler receives CE marking

Iconovo’s strong start to 2020 shows no signs of slowing down as we approach summer. The company just added a CE marking to the list of reached milestones,…

New partnership adds support to development of Iconovo’s Symbicort generic

The Lund-based inhaler experts Iconovo are on the front lines of the fight against asthma, and they recently announced a new partnership dedicated to the…

Analysts see high value in Iconovo business

As Iconovo solidifies its product development and takes aim at a global market, a new analysis by Danske Bank indicates that the inhaler development company…